Orexin B
Orexin receptor agonist
Endogenous hypothalamic neuropeptide from the orexin precursor, reported to favour OX2R over OX1R and studied in sleep-wake and feeding research.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Orexin receptor agonist
- Category
- Neuro, Cognitive & Sleep
- Type
- Single compound
- Development and regulatory status
- Not approved; endogenous neuropeptide used experimentally
What researchers study
Endogenous hypothalamic neuropeptide derived from the same precursor as orexin A. It activates orexin receptors and is reported to favour OX2R over OX1R; studied in sleep-wake regulation and feeding.
Research areas
- Sleep-wake and arousal studies in rodents
- Feeding-behaviour models
- OX2R signalling assays
- Orexin-system pharmacology with receptor antagonists
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- rodent
Orexin-A and -B come from one precursor and both stimulated food consumption in rats
- review
A 2020 review reported OX2R-selective and dual antagonists show more pronounced efficacy in sleep disorders, while OX1R-selective ones look promising for anxiety and addiction
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
